UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

~~Current~~CURRENT ~~Report Pursuant to Section 13 or 15(d) of the~~REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~July~~August 722, 2014

PURAMED BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Minnesota	00-52771	20-5510104
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

Minnesota

(State or other jurisdiction

of incorporation)

00-52771

(Commission

File Number)

20-5510104

(IRS Employer

Identification No.)

1326 Schofield Avenue

Schofield, ~~Wisconsin~~WI 54476

(Address of principal executive offices)

(Zip Code)

(715) 359-6373

Registrant’s telephone number, including area code:

~~¨ Written~~Check ~~communication~~the ~~pursuant~~appropriate box below if the Form 8-K filing is intended to ~~Rule~~simultaneously ~~425~~satisfy ~~under~~the filing obligation of the ~~Securities~~registrant ~~Act~~under ~~(17~~any ~~CFR~~of ~~230.425)~~the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 40240.13e-4(c))

Item 35.~~02 Unregistered~~03 ~~Sale~~Amendments to Articles of ~~Equity~~Incorporation ~~Securities.~~or Bylaws; Change in Fiscal Year

~~The~~On ~~Board~~August of22, ~~Directors~~2014, of PuraMed Bioscience, Inc. (the “Company”) byheld ~~unanimous written consent in lieu of~~ a ~~special~~Special ~~meeting~~Meeting ~~approved, in connection with the designation~~ of ~~Series~~Stockholders ~~A Preferred Stock and Series B Preferred Stock on the terms and conditions approved by the Board of Directors, the issuance of~~ (the “~~Issuance~~Special Meeting”) ~~(i)~~for 51the ~~shares~~purpose of ~~Series A Preferred Stock~~ (~~as defined below~~i) ~~and~~authorizing ~~4,000,000 shares of Series B Preferred Stock to Russell Mitchell,~~ the ~~Company’s~~change ~~Chief Executive Officer,~~ in ~~consideration~~domicile offrom ~~the~~Minnesota ~~cancellation~~to ofNevada ~~400,000,000 shares of the Company’s common stock~~ (the “~~Common~~Domicile ~~Stock~~Change”); and (ii) ~~250,000~~authorizing ~~shares~~a ~~of Series B Preferred Stock to each of two investors, in consideration of the cancellation of 25,000,000 shares each of the Company’s Common Stock. The certificates of designation~~ 1-for-40 ~~the~~reverse ~~Series~~stock Asplit ~~Preferred Stock and~~ (the ~~Series~~“Reverse B Preferred Stock were filed with the Secretary of State of the State of Minnesota on July 7, 2014 and the Issuance was effected, and the shares thereunder issued in accordance with the terms thereof, on July 11, 2014Split”). ~~As of this date the number of issued and outstanding shares of the Company is 1,150,873,676.~~

These securities were not registered under the Securities Act. These securities qualified for exemption under Section 4(2) of the Securities Act since the issuance of securities by us did not involve a public offering. The ~~offering~~shareholders ~~was~~voted ~~not a “public offering” as defined~~ in ~~Section~~favor ~~4(2) due to the insubstantial number~~ of ~~persons involved in~~ the ~~deal,~~change ~~size of the offering, manner of the offering and number of securities offered. We did not undertake an offering~~ in ~~which~~domicile wefrom ~~sold~~Minnesota ~~a high number of securities~~ to aNevada ~~high number of investors. In addition, these shareholders had the necessary investment intent as required by Section 4(2) of the Securities Act since the Conventions Shareholders agreed to~~ and ~~received share certificates bearing a legend stating that such securities are restricted pursuant to Rule 144 of~~ the Securities Act. This restriction ensures that these securities would not be immediately redistributed into the market and therefore not be part of a “public offering.” Based on an analysis of the above factors, we have met the requirements to qualify 1-for-40 ~~exemption~~reverse ~~under~~stock ~~Section~~split ~~4(2) of the Securities Act~~authorization.

Item 35.0307 ~~Material~~Submission ~~Modification~~of Matters to ~~Rights~~a Vote of Security Holders.

On ~~July~~August 722, 2014, the ~~Company~~Domicile ~~amended~~Change ~~its~~and ~~certificate~~Reverse ofSplit ~~incorporation~~were byapproved ~~filing~~at ~~certificates~~the ofSpecial ~~designation~~Meeting. As ~~with Secretary~~ of ~~State~~the close of ~~Minnesota,~~business ~~which~~on ~~designate~~July ~~two~~24, 2014 ~~series~~(the of“Record ~~preferred~~Date”), ~~stock~~1,481,447,416 ~~Series~~shares Aof ~~Preferred~~Common Stock ~~(“Series~~and A51 ~~Preferred~~shares ~~Stock”)~~of ~~and~~ Series BA Preferred Stock ~~(“Series~~were Bissued ~~Preferred~~and ~~Stock”),~~outstanding ~~pursuant~~on tothe ~~which~~Record ~~the~~Date, ~~Company~~with ~~set~~each ~~forth~~share ~~the~~of ~~respective~~Common ~~designation,~~Stock ~~powers,~~entitled ~~rights,~~to ~~privileges,~~one ~~preferences~~vote and ~~restrictions~~each share of the Series A Preferred ~~Stock~~having ~~and~~voting ~~the~~rights ~~Series~~equating Bto ~~Preferred~~30,232,321 ~~Stock. Among other things~~votes, ~~Each~~pursuant ~~one~~to ~~(1)~~the ~~share~~terms of the ~~Series~~Certificate Aof ~~Preferred~~Designations, ~~shall~~Rights ~~have~~and ~~voting~~Preferences ~~rights~~of ~~equal~~Series ~~to(x)~~A ~~0.019607~~Preferred ~~multiplied~~Stock byand the ~~total~~number ~~issued~~of ~~and outstanding~~ shares of Common Stock ~~eligible~~outstanding toas ~~vote at the time~~ of the ~~respective~~Record ~~vote~~Date. (At the ~~“Numerator”)~~Special Meeting, ~~divided by~~ (yi) ~~0.49~~1,750,001,925 ~~minus~~votes, ~~(z)~~or ~~the~~approximately ~~Numerator~~57.9% ~~For purposes~~ of ~~illustration only, if~~ the ~~total issued and~~ outstanding ~~shares~~votes, ofwere ~~Common~~represented ~~Stock~~in ~~eligible~~person toor ~~vote~~by atproxy for the ~~time~~vote ofon the ~~respective~~Domicile ~~vote~~Change isand 5(ii) 1,~~000~~750,~~000~~001,925 ~~the~~votes, ~~voting~~or ~~rights~~approximately of57.9% ~~one share~~ of the ~~Series~~outstanding Avotes, ~~Preferred~~were ~~shall~~represented bein ~~equal~~person toor ~~102,036~~by ~~(0.019607~~proxy xfor ~~5,000,000)~~the /vote ~~0.49)~~on –the ~~(0.019607~~Reverse ~~x 5,000,000) = 102,036)~~Split.

The ~~foregoing~~results ~~description~~ of the ~~Series~~voting Aat ~~Preferred Stock does not purport to be complete and is subject to, and qualified in its entirety by,~~ the ~~Certificate~~Special ofMeeting ~~Designation~~are ~~for the Series A Preferred Stock, a copy of which is attached hereto~~ as ~~Exhibit 3.1 and incorporated herein by reference.~~follows:

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

	For	Against	Abstain
Total Votes Change in Domicile	1,733,467,925	16,284,000	250,000
% Voted For Change in Domicile	99.06%	0.93%	0.01%
	For	Against	Abstain
Total Votes Reverse Stock Split Authorization	1,593,684,427	156,062,438	255,060
% Voted For Reverse Stock Split Authorization	91.07%	8.92%	0.01%

OnAccording ~~July~~to 7,the ~~2014~~results above, the ~~Company~~majority ~~amended its certificate~~ of ~~incorporation~~the bystockholders ~~filing~~present ~~certificates~~at ofthe ~~designation~~meeting, ~~with~~whether ~~Secretary~~in ofperson ~~State~~or ofby ~~Minnesota~~proxy, ~~that~~voted ~~designate~~FOR ~~two~~and ~~series~~thereby ofauthorized ~~preferred~~the ~~stock,~~Domicile ~~Series~~Change Aand ~~Preferred~~voted ~~Stock~~FOR and ~~Series~~thereby Bauthorized ~~Preferred~~the ~~Stock~~Reverse Split.

Fifty-one (51) shares of Series A Preferred Stock, par value $0.001 per share, were authorized. Please see Item 3.03 above for a description of the voting rights for the Series A Preferred Stock.

Five million (5,000,000) shares of Series B Preferred Stock, par value $0.001 per share, were authorized. Each holder of Series B Preferred Stock may, from time to time and at any time, beginning on the date that is six months from the date of issuance of such Series B Preferred Stock, convert any or all of such holder’s shares of Series B Preferred Stock into fully paid and non-assessable shares of Common Stock in an amount equal to one hundred (100) shares of Common Stock for each one (1) share of Series B Preferred surrendered.

The foregoing descriptions of the Series A Preferred Stock and the Series B Preferred Stock do not purport to be complete and are subject to, and qualified in their entirety by, the Certificates of Designation, copies of which are attached hereto as Exhibits 3.1 and 3.2, respectively, and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
3.1		Certificate of Designation of Preferences, Rights and Limitations of the Puramed Bioscience, Inc. Series A Preferred Stock, as filed with the Minnesota Secretary of State on July 7, 2014.*
3.2		Certificate of Designation of Preferences, Rights and Limitations of the Puramed Bioscience, Inc. Series B Preferred Stock, as filed with the Minnesota Secretary of State on July 7, 2014.*

* filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PURAMED BIOSCIENCE, INC.		~~PURAMED BIOSCIENCE, INC.~~
Date: July 11, 2014			By:	/s/ Russell Mitchell
August 26, 2014	By:	/s/ Russell W. Mitchell
				Name: Russell Mitchell
		Name: Russell W. Mitchell
				Title: Chief Executive Officer
		Title: Chief Executive Officer/Chief Financial Officer

Filing Compare · Puramed Bioscience Inc.